Biocon’s revenue grew 31% to ₹5,659 crore and net profit soared 143% to ₹905 crore for the fiscal ended March 31, 2019.
The fiscal that went by was a landmark year for Biologics business, which reported a 97% growth, emerging as a key driver for Biocon’s incremental growth and crossed the $200-million revenue milestone, Biocon said. Syngene, its research services subsidiary, crossed ₹500 crore revenue with a net profit of ₹100 crore in Q4.
To commemorate the 40th anniversary of Biocon, the Board of Directors of the company recommended the issue of one bonus share for every one share held in Biocon.
